Century Therapeutics, Inc.
corporate_fare Company Profile
Century Therapeutics, Inc. (NASDAQ:IPSC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for IPSC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for IPSC spans 8-K, 10-Q, DEF 14A, PRE 14A.
Recent high-impact activity:
- Century Therapeutics Reports Q2 2026 Results: $197.2M Cash Runway into 2029, CNTY-813 IND on Track for Q4
- Century Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances Amid Cost Cuts
- Century Therapeutics Reports Q2 Cash Runway Into 2029, FDA Alignment on CNTY-813 IND Path
- Chief Scientific Officer Transitions to Part-Time Role with Reduced Salary
- Century Therapeutics Shareholders Approve 50% Increase in Authorized Common Stock
Financial Snapshot
Short Interest & Short Volume
30.96 days to coverFINRA reported short interest of 32,026,662 shares in IPSC as of the October 30, 2026 settlement, a 9.9% increase from the prior period — about 31.0 days to cover at its recent average daily volume. On November 19, 2026, 58.7% of IPSC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.